Somewhat Positive Press Coverage Somewhat Unlikely to Affect Depomed (DEPO) Share Price
News coverage about Depomed (NASDAQ:DEPO) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 45.3238065848283 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Depomed, Inc. (DEPO) Downgraded by ValuEngine (americanbankingnews.com)
- DEPO LOSS NOTICE: Rosen Law Firm Reminds Depomed, Inc. Investors of Important Deadline in Class Action – DEPO – GlobeNewswire (press release) (globenewswire.com)
- Pain Management Therapeutics Market to Cross US$ 83.0 Billion by 2024 (mynewsdesk.com)
- Diabetic Neuropathy Market Size to Accelerate at a Rapid CAGR of 5.4% (mynewsdesk.com)
Several equities research analysts recently commented on DEPO shares. ValuEngine raised Depomed from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Royal Bank Of Canada reissued a “hold” rating and issued a $13.00 price target on shares of Depomed in a research note on Tuesday, June 13th. BidaskClub cut Depomed from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Janney Montgomery Scott cut Depomed from a “buy” rating to a “neutral” rating and lowered their price target for the company from $18.00 to $8.00 in a research note on Tuesday, August 8th. Finally, Morgan Stanley cut Depomed from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $12.00 to $5.00 in a research note on Tuesday, August 8th. Four analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. Depomed presently has a consensus rating of “Hold” and an average price target of $14.59.
Shares of Depomed (NASDAQ DEPO) traded up 2.66% on Friday, hitting $5.79. The stock had a trading volume of 1,260,388 shares. Depomed has a 52 week low of $5.67 and a 52 week high of $27.02. The stock’s 50-day moving average price is $6.69 and its 200 day moving average price is $10.50. The company’s market cap is $364.70 million.
Depomed (NASDAQ:DEPO) last issued its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by ($0.52). Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. The business had revenue of $100.00 million for the quarter, compared to the consensus estimate of $100.40 million. During the same quarter in the prior year, the firm posted $0.27 earnings per share. The business’s revenue was down 14.3% compared to the same quarter last year. On average, analysts predict that Depomed will post $0.48 EPS for the current year.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect Depomed (DEPO) Share Price” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-depomed-depo-share-price/1599618.html.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.